who owns semaglutide SURMOUNT-5: Tirzepatide Bests in Head-to-Head Weight Loss Trial Novo Nordisk and D Young

Retatrutide is not yet FDA approved, with approval expected no earlier than mid-2026

Understanding your genetic predisposition to rapid weight regain can inform whether continuous therapy, strategic tapering, or intensive lifestyle support is most appropriate for your physiology

Letter: Another view on private equity in GI by George Dickstein, MD, AGAF Affiliating with a private equity-backed management services organization can empower physician practices to deliver high-quality care at a lower cost

Personalized Consultations Every guest's hair journey is different

A half-inch needle length is appropriate for most subcutaneous injection sites in adults